# HDP-103

Source: https://onco.cc/drugs/hdp-103/  
OnCo record `hdp-103` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

HDP-103 is an experimental antibody-drug conjugate with an amanitin payload from Heidelberg Pharma, in preclinical development for metastatic castration-resistant prostate cancer; development is paused.

## Summary

HDP-103 (PSMA-ATAC) is an antibody-drug conjugate with an amanitin payload (ATAC) from Heidelberg Pharma, with Huadong Medicine as partner. An amanitin conjugate targeting PSMA for metastatic castration-resistant prostate cancer. Its furthest stage is preclinical development, for metastatic castration-resistant prostate cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Heidelberg will not develop it further itself; working with partner Huadong toward a possible phase 1 in China and seeking partners elsewhere (company page). It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Also known as: PSMA-ATAC
- Tags: pipeline
- Code: HDP-103
- Modality: Antibody-drug conjugate with an amanitin payload (ATAC)
- Mechanism: An amanitin conjugate targeting PSMA for metastatic castration-resistant prostate cancer.

## Sources

- Heidelberg Pharma: heidelberg-pharma.com: https://heidelberg-pharma.com/en/research-development/atac-r-projects
- Heidelberg Pharma: heidelberg-pharma.com: https://heidelberg-pharma.com/en/research-development/atac-r-projects

## Connected records

- targets: [PSMA](https://onco.cc/targets/psma/)
- companies: [Heidelberg Pharma](https://onco.cc/companies/heidelberg-pharma/)

---
JSON: https://onco.cc/api/v1/entities/hdp-103.json